We’re excited to confirm that our colleagues in Tulsa, Oklahoma, are prepared to initiate the first human trials of the Turbo O₂ Cap, anticipated to start in Q1 2025 shortly after manufacturing is fully operational. Although human studies are not required for this device, we welcome them to build a stronger body of published research on the Turbo O₂ Cap's efficacy.

As a physician, I understand the importance of published data in assessing a product's performance. The Turbo O₂ Cap has already shown compelling results through animal, cadaver, and engineering lab studies, and this trial in Oklahoma will be an important addition to our story.